Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
Research News
Conference News
Plain English
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
What We Know
Animal Models
Drugs in Trials
Research Tools
Community Calendar
General Information
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.

Michalon A, Sidorov M, Ballard TM, Ozmen L, Spooren W, Wettstein JG, Jaeschke G, Bear MF, Lindemann L. Chronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice. Neuron . 2012 Apr 12 ; 74(1):49-56. PubMed Abstract

Comments on Paper and Primary News
Primary News: Glutamate Receptor Blockers Reverse Fragile X Symptoms in Mice

Comment by:  Bernard Crespi
Submitted 20 April 2012 Posted 25 April 2012
  I recommend this paper

The emerging possibility of reversing neurodevelopmental disorders in children or adults (Ehninger et al., 2008) represents one of the most exciting recent developments in psychiatry.

With regard to effects from modulation of the mGlur5 receptor, of notable interest to schizophrenia researchers might be the suite of recent studies focused on the development of positive allosteric modulators of this receptor for schizophrenia treatment (e.g., Rodriguez et al., 2010; Spear et al., 2011; Gray et al., 2012). Agonists of mGlur5 now have demonstrated efficacy in rodent models of schizophrenia, and await testing in humans.

Michalon et al. (2012), of course, demonstrated strong positive effects of mGlur5 antagonists in ameliorating an animal model of Fragile X syndrome, an autism spectrum condition. These contrasting results of mGlur5 antagonists for an autism spectrum condition and agonists...  Read more

View all comments by Bernard Crespi
Submit a Comment on this Paper
Make a comment on this paper. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory  
*Login Email Address  
*Confirm Email Address  
*Confirm Password  
Remember my Login and Password?  
Get SRF newsletter with recent commentary?  
Enter the code as it is shown below:
This code helps prevent automated registrations.

I recommend this paper

Please note: A member needs to be both registered and logged in to submit a comment.


(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)


SRF News
SRF Comments
Text Size
Reset Text Size
Email this pageEmail this page

Copyright © 2005- 2014 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright